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Abstract
Inﬂammatory activation of monocytes is an essential part of both innate immune responses and the
pathogenesis of conditions such as atherosclerosis. However, the mechanisms which modulate the
response of monocytes to inﬂammatory stimuli are still poorly understood. Here, we report that
tribbles-2 (trb-2) is a novel regulator of inﬂammatory activation of monocytes. Down-regulation of
trb-2 levels potentiates LPS-induced IL-8 production via enhanced activation of the extracellular
signal-regulated kinase and jun kinase mitogen-activated protein kinase (MAPK) pathways. In keeping
with this, the endogenous level of trb-2 expression in human primary monocytes is inversely
correlated to the cell’s ability to produce IL-8. We show that trb-2 is a binding partner and a negative
regulator of selected MAPKs. The potential in vivo relevance of these ﬁndings is highlighted by the
observation that modiﬁed low-density lipoprotein profoundly down-regulates trb-2 expression, which
may, in turn, signiﬁcantly contribute to the inﬂammatory processes in the development of vascular
disease. Taken together, our results deﬁne trb-2 as a potent novel regulator of monocyte biology,
controlling the activation of these cells.
Introduction
The family of tribbles proteins has recently been identiﬁed as
potent regulators of signal processing in a number of physi-
ological and pathological processes. Of the three vertebrate
tribbles, tribbles-2 (trb-2) was ﬁrst described as a gene up-
regulated by mitogens in dog thyroid cells (1, 2). Most of
the recent data on this gene and its protein product are ob-
servational, describing differential expression in prostate
cancer (3), autoimmune uveitis (4) and inﬂammatory condi-
tions (5). Functional studies on trb-2 have demonstrated its
involvement in the progression of mitosis in Xenopus em-
bryos and that it is necessary for the normal development of
the eye and the neuronal system (6). A role for trb-2 in cell
division is suggested as gene expression is up-regulated in
a subset of acute myeloid leukaemias (AML), and retroviral
over-expression of trb-2 induces AML in mice possibly via
enhancing degradation of certain C/EBP protein forms (7, 8).
These results are in line with previous work in Drosophila,
which demonstrated that levels of the ﬂy homologue of
C/EBP (slbo) are critical for programmed mitosis and that
slbo turnover is regulated by tribbles (9).
While the potential importance of tribbles is implicated by
these reports and other literature, less is known about the
molecular mechanism of their action. Members of tribbles
family have been reported to interact and modulate the activity
of signal transduction pathways, including the phosphoinosi-
tide 3-kinase (PI3K)/Akt (10, 11) and the mitogen-activated
protein kinase (MAPK) (12, 13) systems. The functional rele-
vance of tribbles-mediated regulation of these pathways
has been highlighted by a recent report suggesting that trb-2
controls adipocyte differentiation (14). We have shown recently
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smooth muscle cells via action on MAPK pathways and found
this gene to be up-regulated in the wall of atherosclerotic
arteries (15). These observations prompted us to further inves-
tigate the potential involvement of tribbles proteins in cell
types, which play a central role in innate immune responses
as well as in the chronic inﬂammatory disease of the vessel
wall.
Monocytes play a central role in the initiation of innate in-
ﬂammatory responses. Once activated by pathogenic stimuli
or cytokines, they normally reside at the sites of inﬂamma-
tion, differentiate to macrophages and coordinate local
responses via the expression of a range of cytokines and
chemokines, which attract and activate other cell types. It is
therefore of crucial importance to the physiological resolu-
tion of inﬂammation to have effective control mechanisms
in place which control monocyte/macrophage responses.
Activation and recruitment of monocytes to the developing
lesion of the arterial wall are essential in the progression of
atherosclerosis. Once in the lesion, monocytes produce
chemokines, such as IL-8 and cytokines, including IL-1, that
further perpetuate the local inﬂammation. Monocytes dif-
ferentiate into macrophages that can internalize oxidized
low-density lipoprotein (oxLDL) particles, leading to their dif-
ferentiation into foam cells. In addition, binding of modiﬁed
LDL will itself regulate monocyte function.
Among others, activation of MAPK has been widely
reported as a key intracellular signalling network, contributing
to inﬂammatory activation of monocytes, as measured by the
production of IL-8 chemokine, for instance (16–18). However,
mechanisms for the down-regulation of these pathways are
still ill deﬁned. With the recent identiﬁcation of tribbles pro-
teins as regulators of MAPK activation (12, 13), we set out
to investigate the role of tribbles in the inﬂammatory activa-
tion of monocytes. We (5) and others (1, 2, 19–21) have
reported that tribbles expression is regulated by a range of
stimuli, including stress, mitogens and cytokines, suggesting
that control of signalling systems may be achieved through
the modulation of expression of tribbles proteins.
We report here that expression of trb-2 is selectively down-
regulated by acetylated low-density lipoprotein (AcLDL).
The consequence of reduced trb-2 expression is the potentia-
tion of IL-8 production both in THP-1 cells and in human primary
monocytes. Our results demonstrate that trb-2 acts via inhibition
of extracellular signal-regulated kinase (ERK) and jun kinase
(JNK) activation. The molecular action of trb-2 is at the level
of trb-2–mitogen activated protein kinase (MAPKK) complexes,
MKK7 and MEK1, that are binding partners of this protein
in monocyte/macrophages. Further, we show that the kinase-
like domain of trb-2 is sufﬁcient for binding to MAPKKs, as well
as to exert its bioactivity. Co-stimulation of THP-1 cells as well
as human primary monocytes with LPS and modiﬁed low-den-
sity lipoprotein (LDL) leads to the enhancement of IL-8 produc-
tion, probably via down-regulation of trb-2. This raises the
possibility that regulation of trb-2 levels could be a novel con-
trol mechanism of both physiological and pathological inﬂam-
matory activation of monocytes. Putting these observations
together, we suggest that in vivo modulation of trb-2 expres-
sion may be an important regulatory mechanism in monocyte
biology.
Methods
All the experiments described in this study were performed
multiple times (N > 2) and representative datasets are shown.
Ethics
The human samples were obtained under the ethical
approval granted by the North Shefﬁeld Research Ethics
Committee. This study conforms to the principles outlined in
the Declaration of Helsinki.
Cells
THP-1 and Raw 264.7 cells were purchased from American
Type Culture Collection and maintained in RPMI (Invitrogen,
CA, USA) supplemented with 10% FCS (L-glutamine) and
penicillin–streptomycin.
Plasmid constructs
Trb-1 and trb-2 expression plasmids were generated by us-
ing pCDNA3.1(+) (Invitrogen, Paisley, UK) as a backbone.
Protein fragment complementation assay (PCA) fusion pro-
teins were constructed as described before (15). To gener-
ate trb-2DN and -DC-truncated protein expression
constructs, amino acid residues 1–60 and 309–343 were de-
leted by PCR-aided mutagenesis. All constructs have been
fully sequence veriﬁed.
THP-1 transfection with siRNA
Transfections were performed using Nucleofector (Amaxa,
Cologne, Germany) using program U-001 and Cell line
Nucleofector Kit V solution (Amaxa). For most experiments,
1.0 3 10
6 cells were used per nucleofection.
siRNA SmartPool against human trb-2, MKK4, MKK7 and
MEK1 were purchased from Dharmacon (Chicago, IL, USA)
and used according to the manufacturer’s recommendation.
MAPK inhibitor treatment
MEK1 inhibitor (PD98059), p38 MAPK inhibitor (SB203580) and
JNK MAPK inhibitor (SP600125) were purchased from Calbio-
chem (Gibbstown, NJ, USA) and used 20 lM for MEK1 and
JNK MAPK inhibitors and 0.2 lM for p38 MAPK inhibitor. The
cells were treated for 1 h with inhibitors before the LPS treatment.
Immunoblot
Anti-MKK7, Anti-MKK4 and Anti-MEK1 antibodies were pur-
chased from Cell Signalling Technology (Danvers, MA, USA)
and used according to the manufacturer’s recommendation.
Polyclonal antibody against trb-2 was raised against the
N-terminal region of trb-2 by standard techniques.
Protein fragment complementation assay
To conﬁrm the physical interaction between trb-2 and MEK1,
MKK4 and MKK7 in live monocytes, we used the yellow ﬂuo-
rescent protein (YFP)-based PCA (22, 23). This approach is
based on the observation that the interaction of two fusion
proteins, expressing the proteins of interest, coupled to the
N- or C-terminal portion of EYFP will lead to re-folding of the
YFP fragments and will generate a functional ﬂuorophore.
Therefore, by using this approach, the interaction of proteins
can be visualized in live cells. The PCA plasmids trb-2-V2
1544 Trb-2 controls monocyte inﬂammationand MEK1, MKK4/7 -V1 were generated by tagging trb-2
and MKKs with half of Venus mutant YFP (V1 and V2) as de-
scribed before (24). The Venus variant of YFP was used in
this assay since it provides a higher signal than EYFP. MKKs
and Trb-2 were fused to the N-terminal (V1) or to the C-
terminal portions of Venus YFP (V2), respectively. The two
expression constructs (trb-2 and one of the MKKs) were
co-transfected and the YFP signal was visualized by FACS
(Figs 4C and 5A–D) and ﬂuorescent microscopy (Fig. 4E).
As controls, proteins expressing a leucine–zipper in fusion
with the N- or C-terminal region of Venus protein (zip-V1 and
Zip-V2, respectively) were used. When these two proteins are
co-expressed, a strong ﬂuorophore is formed. Therefore, we
used this construct pair as a positive control. To detect the
level of ‘background’ in this assay arising from unspeciﬁc
interactions, the combination of zip-V1 and trb2-V2 constructs
(which are not expected to interact) was co-expressed.
Results
AcLDL reduces trb-2 expression in monocytes
In order to identify molecular regulators of monocyte
responses by modiﬁed LDL in the context of inﬂammation, we
ﬁrst characterized the regulation of trb-2 expression by AcLDL
and LPS in a monocytic cell line, THP-1 cells. Given the recent
reports highlighting an important regulatory function for trb-2
in myeloid cells (7, 8, 25), we focussed our studies on this
member of the tribbles family. oxLDL and AcLDL share many
basic mechanisms of their action, including receptors (al-
though oxLDL may sometimes use additional receptors as
well) and signalling pathways (26–28). THP-1 cells were incu-
bated with AcLDL or LPS and expression of trb-2 was investi-
gated by quantitative real-time PCR (Fig. 1A and B). While
AcLDL incubation resulted in a profound down-regulation of
trb-2 expression, LPS-induced activation resulted in a signiﬁ-
cant but transient down-regulation of trb-2 expression. Next,
we tested whether AcLDL stimulation of THP-1 cells has an
impact on inﬂammatory activation of monocytes, speciﬁcally
on LPS-induced IL-8 production. Our results show that AcLDL
treatment signiﬁcantly potentiates maximally induced IL-8
production by LPS in these cells (Fig. 1C). AcLDL treatment
alone did not induce IL-8 production, ruling out LPS contami-
nation as a source of potentiation in the combined treatment.
To validate our ﬁndings, the ability of human primary mono-
cytes to produce IL-8 in response to LPS stimulation was sim-
ilarly assessed. As shown in Fig. 1(D), co-incubation with
AcLDL increased the amount of IL-8 produced in response
to LPS, similar to that seen in the monocytic cell line, THP-1.
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Fig. 1. AcLDL and LPS modulates trb-2 expression and inﬂammatory activation of monocytes. (A–B) trb-2 messenger RNA expression was
measured in response to AcLDL (A) and LPS (100 ng ll
1) (B) treatment (5 lgm l
1). In order to assess statistical signiﬁcance, one-way analysis
of variance (ANOVA) test with Dunnett’s Multiple Comparison Test was performed. *P < 0.05, **P < 0.01 (C) The impact of 24 h AcLDL and LPS
treatment alone and in combination was studied on IL-8 protein production in THP-1 cells. Cells were lysed and IL-8 levels were quantiﬁed by
ELISA (R&D Systems). One-way ANOVA with Dunnett’s Multiple Comparison Test was performed to analyse the results. *P < 0.05 (D)
Responsiveness of primary monocytes from four healthy volunteers was assessed by stimulating cells with LPS or with co-stimulation by LPS and
AcLDL. IL-8 levels, in response to LPS alone, were used as a unit for normalization for each donor and values measured in samples with LPS-
AcLDL co-stimulation were expressed relative to these. AcLDL treatment alone did not induce the production of IL-8 (data not shown).
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To examine whether the observed down-regulation of trb-2 is
mechanistically involved in LPS-induced monocyte activation,
we reduced trb-2 levels by transfecting siRNA against trb-2
and conﬁrmed suppression as measured by trb-2 RNA
(Fig. 2A) and protein expression (Fig. 2B). As a biologically
relevant marker of monocyte activation, IL-8 production was
induced in siRNA-transfected cells by LPS treatment and
measured by ELISA. The results in Fig. 2(C) show that sitrb-
2-treated THP-1 cells produced signiﬁcantly higher levels of
IL-8, compared with cells transfected with control siRNA. To
further characterize the importance of trb-2 expression in
monocytes, human primary monocytic cells were isolated
from blood, stimulated with LPS and IL-8 production was
assessed by ELISA. We found that the level of IL-8 inversely
correlated to the expression of endogenous trb-2 in primary
monocytes (Fig. 2D).
Activation of MAPK pathways controls IL-8 production and is
modulated by trb-2
Previous reports have demonstrated that the expression of
IL-8 is regulated by MAPK pathways (29–33). In agreement
with this, blocking of JNK or MEK1, but not of p38 activity
by pharmacological kinase inhibitors, resulted in the inhibi-
tion of LPS-induced IL-8 production (Fig. 3A). As the above
data indicated a negative role for trb-2 in IL-8 production,
we hypothesized that trb-2 may exert its effect through re-
ducing MAPK activation. This was tested by comparing JNK
and ERK activation in LPS-stimulated THP-1 cells at normal
or reduced trb-2 levels (Fig. 3B). Western blotting analysis
of MAPK phosphorylation levels showed that sitrb-2 treat-
ment potentiated LPS-dependent MAPK activation. These
observations are compatible with a negative regulatory role
for trb-2 in control of inﬂammatory activation of speciﬁc
MAPK pathways.
Trb-2 modulates IL-8 production via interaction with MAPKKs
Previously, we demonstrated that tribbles-1 and -3 proteins in-
teract with MAPKKs and regulate their activity (12, 13). The
experiments shown above have demonstrated that reduced
Trb-2 levels lead to elevated IL-8 production through en-
hanced activation of the JNK and ERK pathways. This sug-
gests a similar mechanism of action to trb-1 and -3, for trb-2.
Therefore, we investigated the interaction of trb-2 with MKK4/
SEK-1, MKK7 and MEK1, known activators of JNK or ERK,
respectively. Our results show that all three MAPKKs are en-
dogenously expressed in THP-1 cells and that their expres-
sion can be inhibited by speciﬁc siRNA treatment (Fig. 4A).
As expected, down-regulation of levels of these MAPKKs by
siRNA led to impaired IL-8 production, in response to LPS
(Fig. 4B), indicating that all three proteins contribute to the
activation of IL-8 expression in these settings.
Next, we investigated whether trb-2 physically interacts with
the above MAPKKs in monocytic cells by using protein frag-
ment complementation assay (PCA) as described previously
(24). Trb-2 binding to MKK7 and MEK1 but not to MKK4
was detected by FACS analysis (Fig. 4C). As an additional
control, the MEK1–trb-2 complex was also detected in a co-
immunoprecipitation system, as shown in Fig. 4(D). Further
to the above, trb-2/MEK1 and trb-2–MKK7 complexes were
Fig. 2. Down-regulation of trb-2 expression leads to increased IL-8 production. (A) The efﬁciency of trb-2 knockdown by siRNA was assessed
using qRT–PCR [Student’s t-test was performed to analyse the results. **P < 0.01 (A)] or western blot (B). In both cases, b-actin was used as
a housekeeping control. (C) The impact of reduced trb-2 levels on LPS-induced IL-8 production was measured by ELISA. Student’s t-test was
performed to analyse the results. P = 0.041 (D) Responsiveness of primary monocytes from four healthy volunteers were assessed by stimulating
cells with stimulation by LPS. The relative level of IL-8 produced is expressed as fold induction of unstimulated cells. The relationship between the
amount of IL-8 produced and trb-2 expression levels was measured by linear regression. trb-2 levels were normalized to the b-actin qRT–PCR
signal in the same sample.
1546 Trb-2 controls monocyte inﬂammationvisualized by ﬂuorescent microscopy, in the macrophage cell
line Raw264.7 cells, by PCA (Fig. 4E). In agreement with the
FACS results, no interaction between trb-2 and MKK4 was
detected in this assay (data not shown). Thus, we conclude
that trb-2 speciﬁcally interacts with MEK1 and MKK7 but not
with MKK4 in monocyte/macrophage cells.
The kinase-like domain of trb-2 is necessary for MAPKK
binding and for the inhibition of activating protein-1 activation
Tribbles proteins are comprised of an N-terminal, proline-rich
N-terminal domain, a central domain, which is similar to
serine–threonine kinases but thought to be catalytically inac-
tive, and a short C-terminal domain of unknown function
Fig. 3. Trb-2 is an inhibitor of the activation of MAPK pathways in THP-1 cells. (A) The involvement of MAPK pathways in LPS-induced IL-8
production was measured by the use of inhibitors of speciﬁc MAPK pathways. (B) THP-1 cells were transfected with control- or trb-2-speciﬁc
siRNA and the level of activation for MAPKs (ERK and JNK), contributing to IL-8 production, was assayed by western blotting. The images were
digitized and the intensity of the signal quantiﬁed from at least three independent experiments. pMAPK levels were normalized to b-actin. Two-
way analysis of variance was performed to assess statistical signiﬁcance of the results. phospho-JNK: P = 0.0027; phospho-ERK: P = 0.0268.
Fig. 4. Trb-2 interacts with MEK1 and MKK7 but not with MKK4. (A) MEK1, MKK4 and MKK7 are endogenously expressed in THP-1 cells and
their protein expression levels can be down-regulated by speciﬁc siRNAs (24 h post-transfection). (B) THP-1 cells were transfected with
siMAPKK or control siRNA, as indicated, and stimulated by LPS. Production of IL-8 was detected by ELISA. One-way analysis of variance
(ANOVA) with Dunnett’s Multiple Comparison Test was performed to analyse the results. *P < 0.05, **P < 0.01 (C) Interaction between trb-2 and
the above MAPKKs was also investigated in THP-1 cells, using the MAPKK-V1 and trb2-V2 fusion protein expression constructs and analysed by
FACS. Abbreviations: Z, zip; T, trb; M, MAPKK. Co-transfection of zip-v1/trb2-V2 pair was used as a negative control and the zip-v1/zip-v2 pair as
a positive control. One-way ANOVA with Dunnett’s Multiple Comparison Test (with mock) was performed to analyse the results. *P < 0.05, **P <
0.01 (D) Interaction between MEK1 and trb-2 was detected in THP-1 cells by co-immunoprecipitation, which were transfected by trb2-V2 and
MEK1 expression constructs. Trb-2 protein was precipitated by anti-GFP antibody and the binding partner was detected by an anti-MEK1
antibody (left lane). As control, total cell lysate was loaded and probed for MEK1 (right lane). Contamination of Ig heavy chain is indicated on the
ﬁgure (E) Trb–MKK complexes were visualized in Raw264.7 cells. These cells were transfected with the indicated pair of expression vectors,
using electroporation, as for the THP-1 cells. pEGFPN2 was used as a control of transfection efﬁciency and the zip-V1 and zip-2 constructs were
co-transfected to as positive controls for PCA in these cells.
Trb-2 controls monocyte inﬂammation 1547(34). We have demonstrated previously that the central ki-
nase-like domain of tribbles-1 is required for its ability to in-
hibit AP-1 activation, which is a well-characterized target of
stress kinases (13). In addition, we showed recently that this
domain is sufﬁcient for the formation of trb-1–MKK4 com-
plexes (15). However, there are no data available to date to
evaluate whether the kinase-like domain is a generic require-
ment for tribbles action within the protein family. Here, we
performed a similar analysis of trb-2–MAPKK complexes, us-
ing HeLa cells, where we have characterized and validated
the biological mechanism of action of tribbles proteins previ-
ously (12). First, we expressed full-length or truncated trb-2
proteins, the latter lacking either the N- or the C-terminal
tribbles domains. The ability of these proteins to inhibit acti-
vating protein-1 (AP-1) activation was assessed in a lucifer-
ase reporter system, where stress kinase pathways, leading
to the phosphorylation and thus the activation of AP-1 tran-
scription factor was induced by over-expressed MEKK1
(Stratagene, Pathdetect system). We have also shown previ-
ously that AP-1 activation by a range of cytokines is blocked
by tribbles-3 in this system, thus validating the biological im-
portance of tribbles activity in this assay. As shown in Fig.
5(A), both truncated trb-2 versions as well as the full-length
protein inhibited AP-1 activation. In addition, PCA analysis
demonstrated that both MEK1 and MKK7 are able to form
complexes with the truncated trb-2 proteins (Fig. 5B). How-
ever, we note that the level of PCA signal was reduced when
truncated trb-2 were expressed, suggesting that the terminal
regions may contribute to the stability of tribbles–MKK com-
plexes. Experiments testing this hypothesis are currently un-
derway. The speciﬁcity of trb-2/MAPKK interactions, as
detected by PCA, was assessed by FACS (Fig. 5C and D).
Co-expression of an increasing amount of ‘unlabelled’ trb-2
led to a dose-dependent elimination of the YFP signal both
in the trb-2/MKK7 (Fig. 5C) and trb-2–MEK1 (Fig. 5D) com-
plexes, as detected by FACS. In addition, neither MKK-
Venus nor trb-2-Venus fusion proteins interacted with their
zip-Venus counterparts (these were used as positive control
constructs in the system), which further supports the speciﬁc
nature of this interaction.
Discussion
Appreciation of the molecular events occurring in response
to signalling through pattern recognition receptors within
monocytes is essential to understanding innate immunity, as
Fig. 5. Trb-2 kinase-like domain is required for inhibiting AP-1 activation and binding to MKKs. (A) The ability of wild-type trb-2 and truncated
protein forms, lacking either the N- or the C-terminal protein domain, to inhibit MEKK1-induced AP-1 activation was measured in a luciferase
assay system, using HeLa cells as a test system, as before (12, 13). As a control for inhibition of AP-1 activation, wild-type trb-1 protein
expression construct was used. (B) The capacity of trb-2 proteins, lacking the N- or C-terminal protein domains, was assessed by PCA, as
above. MEK1 and MKK7 were expressed in fusion with the N-terminal V1 fragment of YFP; full-length and mutant trb-2 was fused to the
C-terminal V2 fragment, as previously. (C) (D) FACS was used to show the speciﬁcity of interaction between trb-2 and MEK1 and MKK7. Three
doses of untagged trb-2 expression plasmid (relative to the amount of trb2-V2) were co-transfected (1/10, 1/1 and 10/1) with the above PCA
constructs and the mean ﬂuorescence intensity was calculated in the varying samples. One-way analysis of variance with Dunnett’s Multiple
Comparison Test (with no untagged trb-2 transfected) was performed to analyse the results. **P < 0.01.
1548 Trb-2 controls monocyte inﬂammationwell as conditions when these pathways and processes are
subverted in disease pathogenesis. The data presented
here illuminate the role of trb-2, a novel, negative regulator
of MAPK signalling in the context of LPS stimulation of
monocytes. AcLDL, which signals in a manner similar to
oxLDL, down-regulates the expression of trb-2. This, in turn,
leads to enhanced IL-8 production in LPS-stimulated mono-
cyte cells. Data in other systems have revealed the capacity
for tribbles proteins to interact with a range of cell signalling
pathways, including members of the MAPK and PI3K net-
work and a number of transcription factors [reviewed in (34,
35)]. We show here that IL-8 expression is controlled by spe-
ciﬁc MAPK pathways, as demonstrated by pharmacological
inhibition of the ERK and JNK pathways and by siRNA-
mediated suppression of MEK1 and MKK4, MKK7 expres-
sion, respectively. In line with the proposed inhibitory action
of trb-2, siRNA-mediated down-regulation of trb-2 expres-
sion leads to a signiﬁcant increase in JNK and ERK activa-
tion. Our experiments investigating physical interaction
between proteins have shown that trb-2 can interact with
MKK7 or MEK1, activators of ERK and JNK. These data indi-
cate that trb-2 is an important negative regulator of mono-
cyte IL-8 production in response to LPS and controls the
augmentation of this response by AcLDL (Fig. 6A and B).
We have shown that trb-2 comes into close physical prox-
imity with MEK1 and MKK7 but not MKK4. This is in keeping
with the ﬁndings of others which support the mechanism of
action of tribbles through physical interaction with other sig-
nal transduction proteins. This has led to their description
as scaffold/regulatory proteins. Our current observations are
in strong support of this model. However, molecular details
of tribbles/MAPKK interactions and the detailed mode of
tribbles action on activation of kinase cascades remain to
be determined. It is also noteworthy that trb-2 has been
reported to be expressed primarily in the cytoplasm, while
trb-1 and -3 are believed to be nuclear proteins (13, 34).
Currently, there are no published data on the nature and rel-
evance of interaction between MAPK pathways and trb-2.
We suggest that the basic molecular mechanisms responsi-
ble for tribbles action are similar for trb-2 to those we have
reported to trb-1 previously (12, 15). We have carried out
preliminary analysis to characterize the domains of trb-2 pro-
tein necessary for the observed MAPK inhibitory activity and
investigated, whether the domain minimally required for the
inhibition of MAPK activation is also sufﬁcient for the forma-
tion of MAPKK–trb-2 complexes. Our data demonstrate that
the trb-2 kinase-like domain is sufﬁcient for both activities.
These results are in line with our previous reports on trb-1.
The experiments in this study provide evidence that trib-
bles, a novel group of proteins, can act as regulators of in-
nate immune responses in monocytes. Modulation of such
key components may be particularly attractive to pharmaco-
therapy as the predicted outcome of trb-2 up-regulation (or
prevention of down-regulation) would be to reduce innate
immune responsiveness without its total abolition. Based on
this, we believe that further studies exploring the regulation
of tribbles expression in inﬂammatory disease are warranted
to determine whether inhibition of tribbles expression occurs
in these conditions.
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AcLDL acetylated low-density lipoprotein
AML acute myeloid leukaemias
AP-1 activating protein-1
Fig. 6. A model for the role of trb-2 in monocyte biology in inﬂammatory settings. (A) AcLDL uptake by monocytes triggers reduction of trb-2
expression, resulting in a hypersensitive state towards inﬂammatory stimuli, as exempliﬁed by LPS-induced IL-8 production. (B) The molecular
basis of trb-2 regulatory function of MAPKK pathways in the expression of IL-8.
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